Waine G J, McManus D P
Molecular Parasitology Unit, Queensland Institute of Medical Research, Australia.
Bioessays. 1997 May;19(5):435-43. doi: 10.1002/bies.950190511.
Development of a vaccine for schistosomiasis, a parasitic disease currently affecting over 200 million people worldwide, has been targeted as a priority by the World Health Organisation. Research demonstrating the ability of humans to acquire natural immunity to schistosome infection, together with the successful use of attenuated vaccines in animals both under laboratory and field conditions, suggest that development of a human vaccine is feasible. Attenuated vaccines for schistosomiasis are considered neither safe nor practicable for human use, however, and therefore other approaches must be considered. This review examines progress currently being undertaken in a number of different areas towards achieving the goal of a safe and effective human vaccine for schistosomiasis.
血吸虫病是一种目前在全球影响着超过2亿人的寄生虫病,开发针对该病的疫苗已被世界卫生组织列为优先事项。研究表明人类能够获得对血吸虫感染的自然免疫力,同时在实验室和野外条件下减毒疫苗在动物身上的成功使用,表明开发人类疫苗是可行的。然而,用于血吸虫病的减毒疫苗被认为对人类使用既不安全也不可行,因此必须考虑其他方法。本综述考察了目前在多个不同领域为实现开发一种安全有效的血吸虫病人类疫苗这一目标所取得的进展。